PamGene's Scientific Advisory Board is providing scientific direction to PamGene with respect to new applications for our microarray format. The board consists of internationally recognized scientists. They are active in various areas that are relevant to PamGene's scientific and business development like oncology, infectious diseases, bioinformatics, genetics, pharmaceutical research and development, immunology and proteomics. The scientific advisory board helps PamGene to extend its scientific and commercial network considerably and to signal opportunities for its versatile technology and products.
|
|
Dr Bertrand Jordan, Founder and Coordinator of the Marseille-Nice Genopole Genomics Consortium
Bertrand Jordan obtained his PhD in particle physics at CERN, Geneva,then pursued a career in molecular biology within CNRS, France. He directed the Immunology centre in Marseille for a couple of years and later headed up one of the first programs on large scale transcript analysis. He is now formally retired from CNRS but is busy with a number of activities including the co-ordination of the Marseille-Nice Genopole,a consortium set up to develop research in the area of genomics. Bertrand is also active with Ipsogen (spun-out of the CIML in 1999) and presides over their scientific advisory board.
"I first heard of PamGene's technology in 1999, at a microarray meeting in Estonia, and was immediately intrigued and interested. I am happy to have the opportunity of working with this very innovative company to help bring new dimensions to expression profiling, and am convinced of the opportunities open to this high-throughput approach to biomolecular assays." |
|
|
|
|
Dr George Demetri, Associate Professor of Medicine, Dana Farber Cancer Institute (Cambridge, MA)
Dr. Demetri received his undergraduate degree in biochemistry from Harvard College and his medical degree from Stanford University, followed by an internal medicine residency and chief residency at the University of Washington Hospitals , Seattle, Washington and a fellowship in medical oncology at Dana-Farber Cancer Institute and Harvard . He is the Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center as well as Director of the Center for Sarcoma and Bone Oncology at Dana-Farber. He also serves as Executive D irector for Clinical and Translational Research of the global Ludwig Institute for Cancer Research.
"In trying to bring the best science to therapeutic application as quickly as possible, our team and I use all available technologies to unravel the signaling pathways of different forms of cancer. The highly multiplexed nature of the functional read-out directly from cancer cells is a key component of what differentiates the PamGene technology from other assays, and it strikes me that this could inform our thinking about cancer as well as our targeted development of new classes of anticancer agents." |
|
|
|
|
Dr Sharat Singh Senior Scientific Advisor, Rx & Dx; Prometheus Therapeutics & Diagnostics (San Diego, CA)
After gaining his PhD in organic chemistry from the Indian Institute of Science, Bangalore, India and completing a postdoctoral fellowship at Columbia University, New York City, Sharat began his career at Syntex. While at Syntex, Sharat was a key inventor of LOCI technology. After Syntex, Sharat joined ACLARA Biosciences where he was CSO and invented and commercialized eTags.
Sharat has over 20 years of experience in oncology, organic chemistry, pathology, and immunology.
|
|
|
|
|
Dr Mike Yaffe, Associate Professor Biology, MIT Centre for Cancer Research (Cambridge, MA)
Mike Yaffe received his PhD in biophysical chemistry as well as his medical degree from Case Western Reserve University. He then served as resident and fellow in general surgery and critical care medicine at Harvard University. Before joining the MIT faculty, he was a fellow at the Division of Signal Transduction and instructor in medicine and surgery at Harvard.
|
|
|
|
|
